Breakpoint Therapeutics Announces Development Candidate Nomination and Start of IND-Enabling Activities of Potential Best-in-Class Polymerase Theta (Pol θ / POLQ) Inhibitor

Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced.

Breakpoint To Chair and Present at DDR Inhibitors Summit 2024

Breakpoint’s Managing Directors Daniel Speidel and Jon Hollick will attend the DDR Inhibitors Summit 2024 in Boston (30 January- 1 February 2024). At this international meeting, experts from industry and academia gather to share and discuss updates in the development of novel therapeutics targeting the DNA Damage response in cancer cells. Daniel Speidel will chair […]

Breakpoint To Present At Biotech Showcase

Breakpoint’s Managing Director Daniel Speidel will present a company overview during JPM at Biotech Showcase in San Francisco on January 9, 2024. Hilton Union Square 2:15 pm, Franciscan C.

Breakpoint to Present At Tumour Models London Summit

Breakpoint’s Managing Director Jon Hollick will present a talk entitled “Decoding DNA Damage Response (DDR) Efficacy in Tumour Models to Advance Translation into the Clinic” at the 12th Annual Tumour Models  London Summit (06-07 December 2023). He will also participate in the opening plenary panel discussing “How Do You Select the Best Model for Your […]

Breakpoint To Present At LSX Inv€$tival Showcase

Breakpoint’s Managing Director Jon Hollick will present a company overview at the LSX Inv€$tival Showcase in London on November 13, 2023.

Breakpoint To Present At BIO Investor Forum

Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO Investor Forum in San Francisco on October 18, 2023. 10:00am, Franciscan C.

Breakpoint To Present At BIO International Convention 2023

Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO International Convention in Boston on June 7, 2023. 12:15pm, Session Room 104A.

Breakpoint To Present At DDR Inhibitors Summit, 2023

Breakpoint’s Managing Director and Head of Research Jon Hollick will give a talk entitled “Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold” at the DDR Inhibitors Summit in Boston, 24-26 January 2023.

BVF Partners L.P. Joins Breakpoint’s Investor Syndicate

Biotechnology Value Fund (BVF Partners), a San Francisco-based private investment partnership, has contributed capital in an extension of Breakpoint Therapeutics’ last funding round. Gorjan Hrustanovic, Managing Director at BVF Partners, will join Breakpoint’s Advisory Board as an Observer.

Dr. Juan Jaen Joins Breakpoint’s Advisory Board

Breakpoint welcomed Dr. Juan Jaen to its Advisory Board, adding his nearly 40 years of experience at the forefront of drug discovery and development to the company’s resources. He is Co-Founder, President, and member of the Board of Directors of Arcus Biosciences. Prior to founding Arcus, Juan was Co-Founder of Flexus Biosciences and before that […]